TUNE-401 gives Tune Therapeutics an early signal in the race for finite HBV therapy
Find out how Tune Therapeutics’ TUNE-401 data could reshape the chronic hepatitis B cure race and what risks remain for Phase 2.
Pharma & Biotech
Pharma & Biotech
Can Brii Bio’s HBV rebound data move functional cure closer to clinical reality?
HBV cure hopes depend on durability, not just antigen loss. Brii Bio’s APASL data shifts attention to post-treatment control.
Pharma & Biotech
AusperBio’s AHB‑137 enters final testing phase in HBeAg-negative chronic hepatitis B patients
AusperBio Therapeutics has completed patient enrollment in its Phase III AUSHINE trial evaluating AHB‑137 for the treatment of HBeAg-negative chronic hepatitis B. The randomized, double-blind, multicenter study, launched in China under regulatory clearance from the Center for Drug Evaluation, surpassed its initial enrollment goal with over 570 patients enrolled within five months. AHB‑137 is being
Medical Devices & Diagnostics
How Pictor’s ViraScreen-Core is reshaping clinical lab workflows for infectious disease testing
Explore how Pictor’s ViraScreen-Core multiplex antibody assay aligns with evolving CDC hepatitis B testing guidance and what it means for clinical diagnostics.